Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 13


Detection of antibodies against the CB9 to ICB10 region of merozoite surface protein-1 of Plasmodium vivax among the inhabitants in epidemic areas.

Kim TS, Sohn Y, Kim JY, Lee WJ, Na BK, Kang YJ, Lee HW.

Malar J. 2014 Aug 12;13:311. doi: 10.1186/1475-2875-13-311.


The Interplay between Daptomycin and the Immune System.

Kelesidis T.

Front Immunol. 2014 Feb 12;5:52. doi: 10.3389/fimmu.2014.00052. eCollection 2014. Review.


Plasmodium falciparum-specific cellular immune responses after immunization with the RTS,S/AS02D candidate malaria vaccine in infants living in an area of high endemicity in Mozambique.

Barbosa A, Naniche D, Aponte JJ, Manaca MN, Mandomando I, Aide P, Sacarlal J, Renom M, Lafuente S, Ballou WR, Alonso PL.

Infect Immun. 2009 Oct;77(10):4502-9. doi: 10.1128/IAI.00442-09. Epub 2009 Aug 3.


Strategies for developing multi-epitope, subunit-based, chemically synthesized anti-malarial vaccines.

Patarroyo ME, Cifuentes G, Bermúdez A, Patarroyo MA.

J Cell Mol Med. 2008 Oct;12(5B):1915-35. doi: 10.1111/j.1582-4934.2008.00174.x. Review.


Current status of malaria and potential for control.

Phillips RS.

Clin Microbiol Rev. 2001 Jan;14(1):208-26. Review.


Antibodies to malaria vaccine candidates Pvs25 and Pvs28 completely block the ability of Plasmodium vivax to infect mosquitoes.

Hisaeda H, Stowers AW, Tsuboi T, Collins WE, Sattabongkot JS, Suwanabun N, Torii M, Kaslow DC.

Infect Immun. 2000 Dec;68(12):6618-23.


Use of reconstituted influenza virus virosomes as an immunopotentiating delivery system for a peptide-based vaccine.

Pöltl-Frank F, Zurbriggen R, Helg A, Stuart F, Robinson J, Glück R, Pluschke G.

Clin Exp Immunol. 1999 Sep;117(3):496-503.


Supplemental Content

Support Center